Abstract # 198: Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program—A. Brown, at al.
The study included 2,091 patients in phase 2 and 3 clinical trials of Abbvie’s glecaprevir plus pibrentasvir (Mavyret) to treat hepatitis C (HCV) genotypes 1 through 6. The treatment periods were 8, 12 and 16 weeks. The overall cure rates among all patients in phase 2 and 3 studies were greater than or equal to 95%. The adherence rates were analyzed to understand how adherence affected cure rates.
Conclusion: People who were 80% adherent were just as likely to achieve a cure as those who were 100% adherent. Those who were as low as 50% adherent had about a 90% chance of a cure. The factors of non-adherence included alcohol or tobacco use, the presence of compensated cirrhosis, severe kidney impairment, or genotype 3.
Editorial Comments: As a patient, taking all the medications is the most critical strategy for being cured. However, taking every pill, every day can be a challenge. If someone misses a dose, they should contact their medical provider for information about how and when to take their next dose.
There is also a real possibility that missing too many doses could mean that treatment will not work or that someone could develop drug resistance. However, as this study points out missing a dose does not mean that treatment will not work. This study should be very reassuring.
Alan Franciscus is the Executive Director of the Hepatitis C Support Project and the Editor-in-Chief of the HCV Advocate Website.To read the entire newsletter, click here
Share This Page